Title: 3-SUBSTITUTED PYRIDINE DERIVATIVES AS H3 ANTAGONISTS

Abstract: The present invention relates to compounds of formula (I), wherein $R^1$, $R^2$ and $A$ are as defined in the description and claims, and pharmaceutically acceptable salts thereof as well as to pharmaceutical composition comprising these compounds and to methods for their preparation. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
3-substituted pyridine derivatives as H3 antagonists

The present invention is concerned with novel 3-substituted 6-piperazinyl-pyridine derivatives, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful in treating obesity and other disorders.

In particular, the present invention relates to compounds of the general formula

\[
\begin{align*}
R^2 & X \\
N-&(CH_2)_m & \text{N-(CH2)m-} & \text{N-} & N-R^1 \\
H & & & & I
\end{align*}
\]

wherein

- \( R^1 \) is selected from the group consisting of hydrogen, lower alkyl, \( C_3-C_7 \)-alkenyl, \( C_3-C_7 \)-alkynyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, \( C_3-C_7 \)-cycloalkyl, and lower \( C_3-C_7 \)-cycloalkylalkyl;
- \( X \) is \( C(O) \) or \( SO_2 \);
- \( m \) is 0 or 1;
- \( R^2 \) is selected from the group consisting of lower alkyl, \( C_3-C_7 \)-alkenyl, \( C_3-C_7 \)-alkynyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, unsubstituted \( C_3-C_7 \)-cycloalkyl or \( C_3-C_7 \)-cycloalkyl substituted by phenyl, lower \( C_3-C_7 \)-cycloalkylalkyl, lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, unsubstituted pyridyl or pyridyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and \(-NR^3R^4\),
or, in case \( X \) is \( C(O) \), \( R^2 \) can also be lower alkoxy or lower alkoxyalkoxy,
or, in case m is 1, R³ can also be unsubstituted phenyl or phenyl mono- or 
disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl,

R³ is hydrogen or lower alkyl;

R⁴ is selected from the group consisting of lower alkyl, C₃-C₇-alkenyl, C₃-C₇-alkiny1, 
lower alkoxyalkyl, 
C₃-C₇-cycloalkyl, 
C₃-C₇-cycloalkyl substituted by phenyl, 
lower C₃-C₇-cycloalkylalkyl, 
unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower 
alkoxy, halogen or lower halogenalkyl, and 
lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by 
lower alkyl, lower alkoxy, halogen or lower halogenalkyl; or

R³ and R⁴ together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or 
7-membered heterocyclic ring optionally containing a further heteroatom selected 
from nitrogen, oxygen or sulfur, said heterocyclic ring being unsubstituted or 
substituted by one, two or three groups independently selected from lower alkyl, 
lower alkoxy, lower alkoxy carbonyl, o xo, halogen and halogenalkyl, or being 
condensed with a C₅-C₈-cycloalkyl ring or a phenyl ring, said cycloalkyl ring or 
phenyl ring being unsubstituted or substituted by one, two or three groups 
independently selected from lower alkyl, lower alkoxy, halogen and halogenalkyl;

and pharmaceutically acceptable salts thereof;

with the exception of 2,2-dimethyl-N-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]- 
propionamide.

2,2-Dimethyl-N-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-propionamide has 
been described in EP 1 035 115 A1 (F. Hoffmann-La Roche AG) as intermediate for the 
synthesis of 4-phenylpyridine derivatives useful as NK-1 receptor antagonists.

It has been found that the compounds of formula I are antagonists and/or inverse 
agonists at the histamine 3 receptor (H₃ receptor).

Histamine (2-(4-imidazolyl) ethylamine) is one of the aminergic neurotransmitters 
which is widely distributed throughout the body, e. g. the gastrointestinal tract (Burks 
211 – 242). Histamine regulates a variety of digestive pathophysiological events like 
gastric acid secretion, intestinal motility (Leurs et al., Br J. Pharmacol. 1991, 102, pp 179-
185), vasomotor responses, intestinal inflammatory responses and allergic reactions (Raithel et al., Int. Arch. Allergy Immunol. 1995, 108, 127-133). In the mammalian brain, histamine is synthesized in histaminergic cell bodies which are found centrally in the tuberomammillary nucleus of the posterior basal hypothalamus. From there, the cell bodies project to various brain regions (Panula et al., Proc. Natl. Acad. Sci. USA 1984, 81, 2572-2576; Inagaki et al., J. Comp. Neurol 1988, 273, 283 – 300).

According to current knowledge, histamine mediates all its actions in both the CNS and in the periphery through four distinct histamine receptors, the histamine H1, H2 H3 and H4 receptors.

H3 receptors are predominantly localized in the CNS. As an autoreceptor, H3 receptors constitutively inhibit the synthesis and secretion of histamine from histaminergic neurons (Arrang et al., Nature 1983, 302, 832-837; Arrang et al., Neuroscience 1987, 23, 149-157). As heteroreceptors, H3 receptors also modulate the release of other neurotransmitters such as acetylcholine, dopamine, serotonin and norepinephrine among others in both the central nervous system and in peripheral organs, such as lungs, cardiovascular system and gastrointestinal tract (Clapham & Kilpatrick, Br. J. Pharmacol. 1982, 107, 919- 923; Blandina et al. in The Histamine H3 Receptor (Leurs RL and Timmermann H eds, 1998, pp 27-40, Elsevier, Amsterdam, The Netherlands). H3 receptors are constitutively active, meaning that even without exogenous histamine, the receptor is tonically activated. In the case of an inhibitory receptor such as the H3 receptor, this inherent activity causes tonic inhibition of neurotransmitter release. Therefore it may be important that a H3R antagonist would also have inverse agonist activity to both block exogenous histamine effects and to shift the receptor from its constitutively active (inhibitory) form to a neutral state.

The wide distribution of H3 receptors in the mammalian CNS indicates the physiological role of this receptor. Therefore the therapeutic potential as a novel drug development target in various indications has been proposed.

The administration of H3R ligands - as antagonists, inverse agonists, agonists or partial agonists - may influence the histamine levels or the secretion of neurotransmitters in the brain and the periphery and thus may be useful in the treatment of several disorders. Such disorders include obesity, (Masaki et al; Endocrinol. 2003, 144, 2741-2748; Hancock et al., European J. of Pharmacol. 2004, 487, 183-197), cardiovascular disorders such as acute myocardial infarction, dementia and cognitive disorders such as attention deficit hyperactivity disorder (ADHD) and Alzheimer’s disease, neurological disorders such as schizophrenia, depression, epilepsy, Parkinson’s disease, and seizures or convulsions, sleep disorders, narcolepsy, pain, gastrointestinal disorders, vestibular
dysfunction such as Morbus Meniere, drug abuse and motion sickness (Timmermann, J. Med. Chem. 1990, 33, 4-11).

It is therefore an object of the present invention to provide selective, directly acting H3 receptor antagonists respectively inverse agonists. Such antagonists / inverse agonists are useful as therapeutically active substances, particularly in the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

In the present description the term “alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms, more preferably one to ten carbon atoms.

The term “lower alkyl” or “C1-C8-alkyl”, alone or in combination, signifies a straight-chain or branched-chain alkyl group with 1 to 8 carbon atoms, preferably a straight or branched-chain alkyl group with 1 to 6 carbon atoms and particularly preferred a straight or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of straight-chain and branched C1-C8 alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert.-butyl, the isomeric pentyls, the isomeric hexyls, the isomeric heptyls and the isomeric octyls, preferably methyl, ethyl and isopropyl, and most preferred methyl and ethyl.

The term “lower alkenyl” or “C3-C6-alkenyl”, alone or in combination, signifies a straight-chain or branched alkyl group comprising an olefinic bond and up to 8, preferably up to 6, particularly preferred up to 4 carbon atoms. Examples of alkenyl groups are 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl and isobutenyl. A preferred example is 2-propenyl.

The term “lower alkinyl” or “C3-C6-alkinyl”, alone or in combination, signifies a straight-chain or branched alkyl group comprising a triple bond and up to 8, preferably up to 6, particularly preferred up to 4 carbon atoms. Examples of alkinyl groups include 2-propinyl (propargyl), 1-methyl-2-propinyl, 2-butylnyl, 3-butylinyl, 2-pentinyl and 1-pentin-3-yl.

The term “alkoxy” refers to the group R'-O-, wherein R' is alkyl. The term “lower alkoxy” refers to the group R'-O-, wherein R' is lower alkyl and the term "lower alkyl" has the previously given significance ("C1-C8-alkoxy"). Examples of lower alkoxy groups are e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec. butoxy and tert.butoxy, preferably methoxy and ethoxy and most preferred methoxy.
The term “lower alkoxyalkyl” or “C₁₋₈-alkoxy-C₁₋₈-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by an alkoxy group as defined above. Among the preferred lower alkoxyalkyl groups are methoxymethyl, methoxyethyl and ethoxymethyl, with methoxymethyl being especially preferred.

The term “lower alkoxyalkoxy” or “C₁₋₈-alkoxy-C₁₋₈-alkoxy” refers to lower alkoxy groups as defined above wherein at least one of the hydrogen atoms of the lower alkoxy group is replaced by an alkoxy group as defined above. Among the preferred lower alkoxyalkoxy groups are methoxethoxy, methoxypropyloxy and ethoxyethoxy, with methoxethoxy being especially preferred.

The term “halogen” refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.

The term “lower halogenalkyl” or “halogen-C₁₋₈-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a halogen atom, preferably fluoro or chloro, most preferably fluoro. Among the preferred halogenated lower alkyl groups are trifluoromethyl, difluoromethyl, fluoromethyl and chloromethyl, with trifluoromethyl being especially preferred.

The term “lower hydroxyalkyl” or “hydroxy-C₁₋₈-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a hydroxy group. Examples of lower hydroxyalkyl groups are hydroxymethyl or hydroxyethyl.

The term “cycloalkyl” or “C₃₋₁⁷-cycloalkyl” means a cycloalkyl ring containing 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl. The cycloalkyl ring may be substituted as defined herein. Especially preferred is cyclopropyl or cyclopentyl.

The term “lower cycloalkylalkyl” or “C₃₋₁⁷-cycloalkyl-C₁₋₈-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a cycloalkyl group as defined above. Examples of preferred lower cycloalkylalkyl groups are cyclopropylmethyl or cyclopropylmethyl.

The term “lower phenylalkyl” or “phenyl-C₁₋₈-alkyl” refers to lower alkyl groups as defined above wherein at least one of the hydrogen atoms of the lower alkyl group is replaced by a phenyl group. The phenyl ring may be substituted as defined herein. Examples of preferred lower phenylalkyl groups are benzyl, 4-methylbenzyl, 4-
fluorobenzyl, 3-methoxybenzyl and 3,4-dimethoxybenzyl.

The term “form a 4-, 5-, 6- or 7-membered saturated heterocyclic ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulfur” refers to a saturated N-heterocyclic ring, which may optionally contain a further nitrogen, oxygen or sulfur atom, such as azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, or azepanyl. The heterocyclic ring may be unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy, oxo, halogen and halogenalkyl. The heterocyclic ring may also be condensed with a C₅-C₆-cycloalkyl ring or a phenyl ring, said cycloalkyl ring or phenyl ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy, halogen and halogenalkyl. Examples for such a condensed heterocyclic rings are 3,4-dihydro-1H-isoquinoline, 1,3-dihydro-isoindole and octahydroquinoline.

The term "pharmaceutically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable. The salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, preferably hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, salicylic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcysteine and the like. In addition these salts may be prepared form addition of an inorganic base or an organic base to the free acid. Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like. Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyamine resins and the like. The compound of formula I can also be present in the form of zwitterions. Particularly preferred pharmaceutically acceptable salts of compounds of formula I are the hydrochloride salts.

The compounds of formula I can also be solvated, e.g. hydrated. The solvation can be effected in the course of the manufacturing process or can take place e.g. as a consequence of hygroscopic properties of an initially anhydrous compound of formula I.
(hydration). The term pharmaceutically acceptable salts also includes physiologically acceptable solvates.

"Isomers" are compounds that have identical molecular formulae but that differ in the nature or the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "stereoisomers". Stereoisomers that are not mirror images of one another are termed "diastereoisomers", and stereoisomers that are non-superimposable mirror images are termed "enantiomers", or sometimes optical isomers. A carbon atom bonded to four nonidentical substituents is termed a "chiral center".

In detail, the present invention relates to compounds of the general formula

\[
R^2-X-N-(CH_2)_m-NH-N-R^1
\]

wherein

- \( R^1 \) is selected from the group consisting of hydrogen, lower alkyl, \( C_3-C_7 \)-alkenyl, \( C_3-C_7 \)-alkynyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, \( C_3-C_7 \)-cycloalkyl, and lower \( C_3-C_7 \)-cycloalkylalkyl;

- \( X \) is \( \text{C}(\text{O}) \) or \( \text{SO}_2 \);

- \( m \) is 0 or 1;

- \( R^2 \) is selected from the group consisting of lower alkyl, \( C_3-C_7 \)-alkenyl, \( C_3-C_7 \)-alkynyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, unsubstituted \( C_3-C_7 \)-cycloalkyl or \( C_3-C_7 \)-cycloalkyl substituted by phenyl, lower \( C_3-C_7 \)-cycloalkylalkyl, lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, unsubstituted pyridyl or pyridyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and

- \( \text{-NR}^3\text{R}^4 \),

or, in case \( X \) is \( \text{C}(\text{O}) \), \( R^2 \) can also be lower alkoxy or lower alkoxyalkoxy,

or, in case \( m \) is 1, \( R^2 \) can also be unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl,
$R^3$ is hydrogen or lower alkyl;

$R^4$ is selected from the group consisting of lower alkyl, $C_3$-$C_7$-alkenyl, $C_3$-$C_7$-alkinyl, lower alkoxyalkyl, $C_3$-$C_7$-cycloalkyl,

$C_3$-$C_7$-cycloalkyl substituted by phenyl,

lower $C_3$-$C_7$-cycloalkylalkyl,

unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and

lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl; or

$R^3$ and $R^4$ together with the nitrogen atom to which they are attached form a $4$-, $5$-, $6$- or $7$-membered heterocyclic ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulfur, said heterocyclic ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy, lower alkoxy carbonyl, oxo, halogen and halogenalkyl, or being condensed with a $C_3$-$C_6$-cycloalkyl ring or a phenyl ring, said cycloalkyl ring or phenyl ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy, halogen and halogenalkyl;

and pharmaceutically acceptable salts thereof;

with the exception of 2,2-dimethyl-$N$-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-propionamide.

Thus, the substituent $R^1$ is selected from the group consisting of hydrogen, lower alkyl, $C_3$-$C_7$-alkenyl, $C_3$-$C_7$-alkinyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, $C_3$-$C_7$-cycloalkyl and lower $C_3$-$C_7$-cycloalkylalkyl. Preferred compounds of formula I according to the present invention are those, wherein $R^1$ is lower alkyl or $C_3$-$C_7$-cycloalkyl, with those compounds, wherein $R^1$ is $C_3$-$C_7$-cycloalkyl being more preferred, and those compounds, wherein $R^1$ is cyclopentyl, being most preferred. Compounds of formula I, wherein $R^1$ is ethyl or isopropyl, are also very preferred.

$m$ is an integer of 0 or 1. Especially preferred are those compounds of formula I, wherein $m$ is 1. However, compounds of formula I, wherein $m$ is 0, are also a preferred embodiment of the invention.

Further preferred are compounds of formula I according to the present invention, wherein $R^2$ is selected from the group consisting of lower alkyl, $C_3$-$C_7$-alkenyl, $C_3$-$C_7$-alkinyl,
lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, 
unsubstituted C₃-C₇-cycloalkyl or C₃-C₇-cycloalkyl substituted by phenyl, 
lower C₃-C₇-cycloalkylalkyl, 
lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, 
unsubstituted pyridyl or pyridyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and 
-NR³R⁴, 
or, in case X is C(O), R² can also be lower alkoxy or lower alkoxyalkoxy.

Within this group, compounds of formula I, wherein R² is selected from the group consisting of lower alkyl, C₂-C₇-cycloalkyl and C₃-C₇-cycloalkyl substituted by phenyl, are preferred.

Furthermore, compounds of formula I are preferred, wherein R² is lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl.

Also preferred are compounds of formula I of the present invention, wherein R² is the group -NR³R⁴.

More preferred are those compounds of formula I, wherein R² is the group -NR³R⁴ and R³ is hydrogen or lower alkyl;

R⁴ is selected from the group consisting of lower alkyl, C₃-C₇-alkenyl, C₃-C₇-alkinyl, 
C₃-C₇-cycloalkyl, 
C₃-C₇-cycloalkyl substituted by phenyl, 
lower C₃-C₇-cycloalkylalkyl, 
unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and 
lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl; or

R³ and R⁴ together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocyclic ring optionally containing a further heteroatom selected from nitrogen, oxygen or sulfur, said heterocyclic ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy, oxo, halogen and halogenalkyl, or being condensed with a phenyl ring, said phenyl ring being unsubstituted or substituted by one, two or three groups independently selected from lower alkyl, lower alkoxy, halogen and halogenalkyl.
Especially preferred are those compounds of formula I, wherein $R^3$ and $R^4$ are lower alkyl.

Another group of preferred compounds of formula I are those, wherein $R^2$ is the group $-NR^3R^4$, $R^3$ is hydrogen and $R^4$ is selected from the group consisting of lower alkyl, $C_3$-$C_7$-alkenyl, $C_3$-$C_7$-alkinyl, $C_3$-$C_7$-cycloalkyl, $C_3$-$C_7$-cycloalkyl substituted by phenyl, lower $C_3$-$C_7$-cycloalkylalkyl, unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl.

Those compounds, wherein $R^3$ is hydrogen and $R^4$ is lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, are especially preferred.

Furthermore, compounds of formula I of the present invention are preferred, wherein $m$ is 1 and $R^2$ is unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl.

A preferred group of compounds of formula I are those, wherein X is $SO_2$. These are the compounds having the formula

$$\text{I-A}$$

wherein $R^1$, $R^2$ and $m$ are as defined hereinbefore.

Furthermore, compounds of formula I are preferred, wherein X is $C(O)$. These are compounds having the formula
I-B

wherein R¹, R² and m are as defined hereinbefore.

Within this group, those compounds are especially preferred wherein X is C(O) and R² is –NR³R⁴, thus meaning compounds of the formula

I-C

wherein R¹, R³, R⁴ and m are as defined hereinbefore.

Examples of preferred compounds of formula I are the following:

1-[6-(4-ethylpiperazin-1-yl)-pyridin-3-yl]-3-propyl-urea,
1-cyclohexyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-p-tolyl-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-fluoro-phenyl)-urea,
1-cyclohexyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,
1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,

1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-fluoro-phenyl)-urea,

1-cyclohexyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,

5 1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-phenyl-urea,

1-benzyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,

1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-o-tolyl-urea,

1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-m-tolyl-urea,

1-(2-chloro-phenyl)-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,

10 1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,

1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,

1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea,

1-(4-fluoro-phenyl)-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,

1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-propyl-urea,

15 1-cyclohexyl-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,

1-benzyl-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,

1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-m-tolyl-urea,

1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-p-tolyl-urea,

1-(2-chloro-phenyl)-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,

20 1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,

1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,

1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea,

1-(4-fluoro-phenyl)-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,

N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
N-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
cyclohexanecarboxylic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-amide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-phenyl-acetamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-(4-fluoro-phenyl)-acetamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-(3-methoxy-phenyl)-acetamide,
2-(3,4-dimethoxy-phenyl)-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-acetamide,
[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid 2-methoxy-ethyl ester,
[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester,
cyclopropanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-butyramide,
cyclobutanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
cyclopentanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-ethyl-butyramide,
cyclohexanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
2-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-nicotinamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-phenyl-acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(4-fluoro-phenyl)-acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3-methoxy-phenyl)-acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3,4-dimethoxy-phenyl)-acetamide,
[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid ethyl ester,
[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid 2-methoxy-ethyl ester,
[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester,
cyclohexanecarboxylic acid [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amide,
2-(3,4-dimethoxy-phenyl)-N-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-acetamide,
[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid ethyl ester,
[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-butyramide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-(4-fluoro-phenyl)-acetamide,
ethanesulfonic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide,
propane-1-sulfonic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminosulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenyl-methanesulfonamide,
C-(4-chloro-phenyl)-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-methanesulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-fluoro-benzenesulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-fluoro-benzenesulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-4-fluoro-benzenesulfonamide,
2-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
4-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-(4-fluoro-benzyl)-urea,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide,
N-[6-(4-Ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-(4-fluoro-phenyl)-acetamide,
ethanesulfonic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide,
propane-1-sulfonic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminosulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenyl-methanesulfonamide,
C-(4-chloro-phenyl)-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-methanesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-fluoro-benzenesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-fluoro-benzenesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-4-fluoro-benzenesulfonamide,
2-chloro-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
4-chloro-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
4-methyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-
amide,
2,6-dimethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-
yl]-amide,
4-trifluoromethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-
pyridin-3-yl]-amide,
1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl carbamoyl]-piperidine-4-carboxylic acid ethyl ester,
octahydro-quinoline-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-
amide,
octahydro-isoquinoline-2-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-
yl]-amide,
2-trifluoromethyl-pyrrolidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-
pyridin-3-yl]-amide,
2-isopropyl-pyrrolidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
1,3-dihydro-isoindole-2-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-isopropyl-1-(2-methoxy-ethyl)urea,
azepane-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-ethyl-1-phenyl-urea,
3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-(4-methoxy-phenyl)-1-methyl-urea,
3,4-dihydro-2H-quinoline-1-carboxylic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-amide,
3,4-dihydro-2H-quinoline-1-carboxylic acid [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amide,
and pharmaceutically acceptable salts thereof.

Particularly preferred compounds of formula I of the present invention are the following:
1-benzyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-byclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,
1-benzyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulphonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3,4-dimethoxy-phenyl)acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminosulphonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenyl-
methanesulfonamide,

C-(4-chloro-phenyl)-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-
methanesulfonamide,

2,6-dimethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-
yl]-amide,

and pharmaceutically acceptable salts thereof.

Furthermore, the pharmaceutically acceptable salts of the compounds of formula I
and the pharmaceutically acceptable esters of the compounds of formula I individually
constitute preferred embodiments of the present invention.

Compounds of formula I may form acid addition salts with acids, such as
conventional pharmaceutically acceptable acids, for example hydrochloride,
hydrobromide, phosphate, acetate, fumarate, maleate, salicylate, sulphate, pyruvate,
citrate, lactate, mandelate, tartrate, and methanesulphonate. Preferred are the
hydrochloride salts. Also solvates and hydrates of compounds of formula I and their salts
form part of the present invention.

Furthermore, the N-atom of the pyridine ring can be present as an N-oxide group.
Such N-oxides of compounds of formula I also form part of the present invention.

Compounds of formula I can have one or more asymmetric carbon atoms and can
exist in the form of optically pure enantiomers, mixtures of enantiomers such as, for
example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers,
diastereoisomeric racemates or mixtures of diastereoisomeric racemates. The optically
active forms can be obtained for example by resolution of the racemates, by asymmetric
synthesis or asymmetric chromatography (chromatography with a chiral adsorbens or
eluant). The invention embraces all of these forms.

It will be appreciated, that the compounds of general formula I in this invention
may be derivatised at functional groups to provide derivatives which are capable of
conversion back to the parent compound in vivo. Physiologically acceptable and
metabolically labile derivatives, which are capable of producing the parent compounds of
general formula I in vivo are also within the scope of this invention.
A further aspect of the present invention is the process for the manufacture of compounds of formula I as defined above, which process comprises

a) reacting a compound of the formula II

\[
\begin{align*}
\text{H}_2\text{N}-(\text{CH}_2)_m & \quad \text{II} \\
\text{N} & \quad \text{N-R}^1 \\
\end{align*}
\]

wherein \( R^1 \) and \( m \) are as defined herein before, with a sulfonylchloride or sulfamoylchloride of the formula III

\[
\begin{align*}
\text{R}^2-\text{SO}_2-\text{Cl} & \quad \text{III} \\
\end{align*}
\]

wherein \( R^2 \) is as defined herein before, to obtain a compound of the formula I-B

\[
\begin{align*}
\text{R}^2 & \quad \text{O} \\
\text{O} & \quad \text{S} \\
\text{N}-(\text{CH}_2)_m & \quad \text{N-R}^1 \\
\text{H} & \quad \text{N} \\
\end{align*}
\]

\[
\text{I-A}
\]

wherein \( R^1, R^2 \) and \( m \) are as defined herein before, or

b) reacting a compound of the formula II

\[
\begin{align*}
\text{H}_2\text{N}-(\text{CH}_2)_m & \quad \text{II} \\
\text{N} & \quad \text{N-R}^1 \\
\end{align*}
\]

wherein \( R^1 \) and \( m \) are as defined herein before, with a chloride of the formula IV

\[
\begin{align*}
\text{R}^2-\text{C(O)Cl} & \quad \text{IV} \\
\end{align*}
\]

wherein \( R^2 \) is as defined herein before, to obtain a compound of the formula I-A
wherein R\(^1\), R\(^2\) and m are as defined herein before, or

c) reacting a compound of the formula II

\[
\text{H}_2\text{N}-(\text{CH}_2)_m-\text{N}=[\text{N}-(\text{CH}_2)_m-\text{N}]-\text{R}^1
\]

II

wherein R\(^1\) and m are as defined herein before,
with an isocyanate of the formula V

\[
\text{R}^4-\text{N}=\text{C}=\text{O} \quad \text{V}
\]

wherein R\(^4\) is as defined herein before,
to obtain a compound of the formula I-C

\[
\text{R}^3\text{N}-\text{O} \quad \text{R}^4\text{N}-\text{C}-(\text{CH}_2)_m-\text{N}=[\text{N}-(\text{CH}_2)_m-\text{N}]-\text{R}^1
\]

I-C

wherein R\(^3\) is hydrogen and R\(^1\), R\(^4\) and m are as defined herein before,
and if desired, converting the compound of formula I-A, I-B or I-C into a pharmacologically acceptable salt.

In more detail, the compounds of formula I can be manufactured by the methods given below, by the methods given in the examples or by analogous methods.

Appropriate reaction conditions for the individual reaction steps are known to a person skilled in the art. Starting materials are either commercially available or can be prepared
by methods analogous to the methods given below, by methods described in references cited in the text or in the examples, or by methods known in the art.

The preparation of compounds of formula I of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following scheme. The skills required for carrying out the reaction and purification of the resulting products are known to those in the art. The substituents and indices used in the following description of the processes have the significance given herein before unless indicated to the contrary.

Compounds of general formula I can be prepared according to scheme 1 as follows:

a) The coupling of chloro substituted pyridine derivatives with piperazines is widely described in literature and the procedures are known to those in the art (For reaction conditions described in literature affecting such reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999). 2-Chloro-5-cyanopyridine (VI) or 2-chloro-5-nitropyridine (IX) can conveniently be transformed to the respective pyridine derivative VIII or X through reaction with a piperazine derivative VII (either commercially available or accessible by methods described in references or by methods known in the art; as appropriate).

The reaction can be carried out in the presence or the absence of a solvent and in the presence or the absence of a base. We find it convenient to carry out the reaction in a solvent like water and/or dimethylformamide (DMF) and in the presence of a base like diisopropyl-ethylamine (DIPEA). There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples for suitable solvents include DMF, dichloromethane (DCM), dioxane, tetrahydrofuran (THF), and the like. There is no particular restriction on the nature of the base used in this stage, and any base commonly used in this type of reaction may equally be employed here. Examples of such bases include triethylamine and diisopropylethylamine, and the like. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. We find it convenient to carry out the reaction with heating from ambient temperature to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. A period of from 0.5 h to several days will usually suffice to yield pyridine derivatives VIII or X.
However, in the cases where the desired piperazine derivative is not easily accessible, an alternative route can be pursued leading to the pyridine derivatives VIII or X.

Piperazine (VII; $R^1 = H$) is reacted with 2-chloro-5-cyanopyridine (VI) or 2-chloro-5-nitropyridine (IX) to access the respective pyridine derivative VIII or X ($R^1 = H$). The reaction can be carried out in the presence or the absence of a solvent and in the
presence or the absence of a base. We find it convenient to carry out the reaction in a solvent like water and/or dimethylformamide (DMF) and in the presence of a base like triethylamine. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples for suitable solvents include: DMF, dichloromethane (DCM), dioxane, THF, and the like. There is no particular restriction on the nature of the base used in this stage, and any base commonly used in this type of reaction may equally be employed here. Examples of such bases include triethylamine and diisopropylethylamine, and the like. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. We find it convenient to carry out the reaction with heating from ambient temperature to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 h to several days will usually suffice to yield pyridine derivatives VIII or X.

Subsequently, to access the pyridine derivatives VIII or X (R\(^1\) ≠ H) the intermediate is subjected to reductive amination reaction conditions with suitable aldehydes or alkylation reaction conditions with suitable alkylation reagents. The reaction conditions for either reaction are widely described in literature and the procedures are known to those in the art (For reaction conditions described in literature affecting such reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999).

b) The reduction of the cyano or nitro functionality in VIII or X respectively can be achieved under various reducing reaction conditions to access the aminomethyl pyridine derivatives II-A (compounds of formula II wherein m is 1) or the aminopyridine derivatives II-B (compounds of formula II wherein m is 0). The reaction conditions for either reaction are widely described in literature and the procedures are known to those in the art (For reaction conditions described in literature affecting such reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999). We find it convenient to hydrogenate VIII or X over Raney Nickel or palladium/charcoal (Pd/C) in a solvent and in the presence or absence of an acid. We find it convenient to carry out the reaction in a solvent like methanol or ethyl acetate. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples for suitable solvents include: methanol, ethanol, ethyl acetate,
and the like. There is no particular restriction on the nature of the acid used in this stage, and any base commonly used in this type of reaction may equally be employed here. Examples of such acids include acetic acid or HCl, and the like. The reduction can be achieved through hydrogen, however any other reducing agents employed in such reaction might equally be employed here. Neither the precise hydrogen pressure nor the precise reaction temperature are critical to the invention. The reaction can take place over a wide range of temperatures, and a wide range of hydrogen pressure. We find it convenient to carry out the reaction with heating from ambient temperature to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 h to several days will usually suffice to yield pyridine derivatives II-A (m is 1).

c) Sulfonamides, amides, carbamates and ureas can be prepared from suitable starting materials according to methods known in the art. The conversion of the amino-moiety in II-A or II-B to access sulfonamides, amides, carbamates and ureas can be affected by methods described in literature. For example, the conversion of the amine derivatives II to access compounds of the general formula I is affected by reaction of II with suitable with sulfonyl chlorides or sulfamoyl chlorides (compounds of formula III) or acid chlorides, chloroformates, or carbonate esters (compounds of formula IV as defined herein before) or with isocyanates (compounds of formula V), respectively, in a solvent like dichloromethane and in the presence or the absence of a base. The compounds of formula III, IV or V are known or can be prepared by known methods. There is no particular restriction on the nature of the solvent to be employed, provided that it has no adverse effect on the reaction or the reagents involved and that it can dissolve the reagents, at least to some extent. Examples for suitable solvents include: chloroform, or dioxane, THF, and the like. There is no particular restriction on the nature of the base used in this stage, and any base commonly used in this type of reaction may equally be employed here. Examples of such bases include triethylamine and diisopropylethyl-amine, and the like. The reaction can take place over a wide range of temperatures, and the precise reaction temperature is not critical to the invention. We find it convenient to carry out the reaction with heating from ambient temperature to reflux. The time required for the reaction may also vary widely, depending on many factors, notably the reaction temperature and the nature of the reagents. However, a period of from 0.5 h to several days will usually suffice to yield pyridine derivatives I. For reaction conditions described in literature affecting such reactions see for example: Comprehensive Organic Transformations: A Guide to Functional Group Preparations, 2nd Edition, Richard C. Larock. John Wiley & Sons, New York, NY. 1999.
As described above, the compounds of formula I of the present invention can be used as medicaments for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors. Examples of such diseases are obesity, metabolic syndrome (syndrome X), neurological diseases including Alzheimer’s disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, attention deficit hyperactivity disorder, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson’s disease, multiple sclerosis, stroke, dizziness, schizophrenia, depression, addiction, motion sickness and sleep disorders including narcolepsy, and other diseases including asthma, allergy, allergy-induced airway responses, congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders. The use as medicament for the treatment and/or prevention of obesity is preferred.

The invention therefore also relates to pharmaceutical compositions comprising a compound as defined above and a pharmaceutically acceptable carrier and/or adjuvant.

Further, the invention relates to compounds as defined above for use as therapeutically active substances, particularly as therapeutic active substances for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors. Examples of such diseases are obesity, metabolic syndrome (syndrome X), neurological diseases including Alzheimer’s disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, attention deficit hyperactivity disorder, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson’s disease, multiple sclerosis, stroke, dizziness, schizophrenia, depression, addiction, motion sickness and sleep disorders including narcolepsy, and other diseases including asthma, allergy, allergy-induced airway responses, congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders.

In another embodiment, the invention relates to a method for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors. Examples of such diseases are obesity, metabolic syndrome (syndrome X), neurological diseases including Alzheimer’s disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, attention deficit hyperactivity disorder, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson’s disease, multiple sclerosis, stroke, dizziness, schizophrenia, depression, addiction, motion sickness and sleep disorders including narcolepsy, and other diseases including asthma, allergy, allergy-induced airway responses, congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders. A method for the treatment and/or prevention of obesity is preferred.
The invention further relates to the use of compounds of formula I as defined above for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors. Examples of such diseases are obesity, metabolic syndrome (syndrome X), neurological diseases including Alzheimer’s disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, attention deficit hyperactivity disorder, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson’s disease, multiple sclerosis, stroke, dizziness, schizophrenia, depression, addiction, motion sickness and sleep disorders including narcolepsy, and other diseases including asthma, allergy, allergy-induced airway responses, congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders. The use of compounds of formula I as defined above for the treatment and/or prevention of obesity is preferred.

In addition, the invention relates to the use of compounds of formula I as defined above for the preparation of medicaments for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors. Examples of such diseases are obesity, metabolic syndrome (syndrome X), neurological diseases including Alzheimer’s disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive deficit, attention deficit hyperactivity disorder, epilepsy, neuropathic pain, inflammatory pain, migraine, Parkinson’s disease, multiple sclerosis, stroke, dizziness, schizophrenia, depression, addiction, motion sickness and sleep disorders including narcolepsy, and other diseases including asthma, allergy, allergy-induced airway responses, congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders. The use of compounds of formula I as defined above for the preparation of medicaments for the treatment and/or prevention of obesity is preferred.

The compounds of formula I and their pharmaceutically acceptable salts possess valuable pharmacological properties. Specifically, it has been found that the compounds of the present invention are good histamine 3 receptor (H3R) antagonists and/or inverse agonists.

The following test was carried out in order to determine the activity of the compounds of formula (I).

**Binding assay with \(^3\)H-(R)\(\alpha\)-methylhistamine**


An appropriate amount of membrane (60 to 80 \(\mu\)g protein/well) was incubated with increasing concentrations of \(^3\)H(R)\(\alpha\)-Methylhistamine di-hydrochloride (0.10 to 10
nM). Non specific binding was determined using a 200 fold excess of cold (R)α-Methylhistamine dihydrobromide (500 nM final concentration). The incubation was carried out at room temperature (in deep-well plates shaking for three hours). The final volume in each well was 250 μl. The incubation was followed by rapid filtration on GF/B filters (pre-soaked with 100 μl of 0.5% PEI in Tris 50 mM shaking at 200 rpm for two hours). The filtration was made using a cell-harvester and the filter plates were then washed five times with ice cold washing buffer containing 0.5 M NaCl. After harvesting, the plates were dried at 55 °C for 60 min, then we added scintillation fluid (Microsint 40, 40 microl in each well) and the amount of radioactivity on the filter was determined in Packard top-counter after shaking the plates for two hours at 200 rpm at room temperature.

Binding Buffer: 50 mM Tris-HCl pH 7.4 and 5 mM MgCl₂ 6H₂O pH 7.4. Washing Buffer: 50 mM Tris-HCl pH 7.4 and 5 mM MgCl₂ 6H₂O and 0.5 M NaCl pH 7.4.

Indirect measurement of affinity of H3R inverse agonists: twelve increasing concentrations (ranging from 10 μM to 0.3 nM) of the selected compounds were always tested in competition binding experiments using membrane of the human HR3-CHO cell line. An appropriate amount of protein, e.g. approximately 500cpm binding of RAMH at Kd, were incubated for 1 hour at room temperature in 250 μl final volume in 96-well plates in presence of ³H(R)α-Methylhistamine (1 nM final concentration = Kd).

Non-specific binding was determined using a 200 fold excess of cold (R)α-Methylhistamine dihydrobromide.

All compounds were tested at a single concentration in duplicates. Compounds that showed an inhibition of [³H]-RAMH by more than 50% were tested again to determine IC₅₀ in a serial dilution experiment. Ki’s were calculated from IC₅₀ based on Cheng-Prusoff equation (Cheng, Y, Prusoff, WH (1973) Biochem Pharmacol 22, 3099-3108).

The compounds of the present invention exhibit Ki values within the range of about 1 nM to about 1000 nM, preferably of about 1 nM to about 100 nM, and more preferably of about 1 nM to about 30 nM. The following table shows measured values for some selected compounds of the present invention.

The following table shows measured values for some selected compounds of the present invention.
<table>
<thead>
<tr>
<th></th>
<th>$K_i$ (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Example 3</td>
<td>39</td>
</tr>
<tr>
<td>Example 34</td>
<td>81</td>
</tr>
<tr>
<td>Example 53</td>
<td>40</td>
</tr>
</tbody>
</table>

The compounds of formula (I) and their pharmaceutically acceptable salts and esters can be used as medicaments, e.g. in the form of pharmaceutical preparations for enteral, parenteral or topical administration. They can be administered, for example, perorally, e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatine capsules, solutions, emulsions or suspensions, rectally, e.g. in the form of suppositories, parenterally, e.g. in the form of injection solutions or infusion solutions, or topically, e.g. in the form of ointments, creams or oils.

The production of the pharmaceutical preparations can be effected in a manner which will be familiar to any person skilled in the art by bringing the described compounds of formula (I) and their pharmaceutically acceptable, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.

Suitable carrier materials are not only inorganic carrier materials, but also organic carrier materials. Thus, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts can be used as carrier materials for tablets, coated tablets, dragées and hard gelatine capsules. Suitable carrier materials for soft gelatine capsules are, for example, vegetable oils, waxes, fats and semi-solid and liquid polyols (depending on the nature of the active ingredient no carriers are, however, required in the case of soft gelatine capsules). Suitable carrier materials for the production of solutions and syrups are, for example, water, polyols, sucrose, invert sugar and the like. Suitable carrier materials for injection solutions are, for example, water, alcohols, polyols, glycerol and vegetable oils. Suitable carrier materials for suppositories are, for example, natural or hardened oils, waxes, fats and semi-liquid or liquid polyols. Suitable carrier materials for topical preparations are glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and cellulose derivatives.
Usual stabilizers, preservatives, wetting and emulsifying agents, consistency-improving agents, flavour-improving agents, salts for varying the osmotic pressure, buffer substances, solubilizers, colorants and masking agents and antioxidants come into consideration as pharmaceutical adjuvants.

The dosage of the compounds of formula (I) can vary within wide limits depending on the disease to be controlled, the age and the individual condition of the patient and the mode of administration, and will, of course, be fitted to the individual requirements in each particular case. For adult patients a daily dosage of about 1 mg to about 1000 mg, especially about 1 mg to about 100 mg, comes into consideration.

Depending on the dosage it is convenient to administer the daily dosage in several dosage units.

The pharmaceutical preparations conveniently contain about 0.1-500 mg, preferably 0.5-100 mg, of a compound of formula (I).

The following examples serve to illustrate the present invention in more detail.

They are, however, not intended to limit its scope in any manner.

Examples

Intermediate 1

1-Ethyl-4-(5-nitro-pyridin-2-yl)-piperazine

A mixture of 2 g (13 mmol) 2-chloro-5-nitro-pyridine and 0.76 g (6 mmol) N,N-diisopropylethylamine in 21 ml water and 4 ml DMF was heated to 80 °C. During 2 min 1.73 g (15 mmol) N-ethylpiperazine was added and the mixture was kept for an additional hour at 80 °C. The yellow precipitate was filtered off and washed three times with 4 ml water and dried for 16 h under vacuum to yield 2.48 g (83 %) of the title compound as yellow crystals. (m/e): 237.1 (MH⁺; 100%).

Intermediate 2

6-(4-Ethyl-piperazin-1-yl)-pyridin-3-ylamine

A mixture of 2.47 g (10 mmol) 1-ethyl-4-(5-nitro-pyridin-2-yl)-piperazine and 0.247 g Pd/C (10 %) in 25 ml methanol was treated with 1 bar hydrogen at room temperature for 2 h. After filtration the mixture was evaporated to dryness to yield 2.12 g (98 %) of the title compound as colourless solid. (m/e): 207.3 (MH⁺; 100%).
Intermediate 3

1-Isopropyl-4-(5-nitro-pyridin-2-yl)-piperazine

According to the procedure described for the synthesis of intermediate 1 1-isopropyl-4-(5-nitro-pyridin-2-yl)-piperazine was synthesised from 2-chloro-5-nitropyridine and N-isopropylpiperazine to yield 97% of the title compound as yellow crystals. (m/e): 251.1 (MH⁺; 100%).

Intermediate 4

6-(4-Isopropyl-piperazin-1-yl)-pyridin-3-ylamine

According to the procedure described for the synthesis of intermediate 2 6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine was synthesised from 1-isopropyl-4-(5-nitro-pyridin-2-yl)-piperazine through hydrogenation to yield the title compound which was used without further purification in the following step. (m/e): 221.1 (MH⁺; 100%).

Intermediate 5

1-Cyclopentyl-4-(5-nitro-pyridin-2-yl)-piperazine

According to the procedure described for the synthesis of intermediate 1 1-cyclopentyl-4-(5-nitro-pyridin-2-yl)-piperazine was synthesised from 2-chloro-5-nitropyridine and N-cyclopentylpiperazine to yield 87% of the title compound as yellow crystals. (m/e): 277.1 (MH⁺; 100%).

Intermediate 6

6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine

According to the procedure described for the synthesis of intermediate 2 6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine was synthesised from 1-cyclopentyl-4-(5-nitro-pyridin-2-yl)-piperazine through hydrogenation to yield 98% of the title compound as colourless crystals. (m/e): 247.1 (MH⁺; 100%).

Intermediate 7

1-Isobutyl-4-(5-nitro-pyridin-2-yl)-piperazine

A mixture of 7 g (34 mmol) 1-(5-nitro-pyridin-2-yl)-piperazine (commercially available), 3.15 g (44 mmol) isobutyraldehyde, 10.7 g (50 mmol) sodium trisacetoxyborohydride in 140 ml THF and 3 ml acetic acid was stirred at room
temperature for 16 h. After addition of 50 ml water, THF was removed under vacuum. The residue was taken up in 300 ml water and 400 ml ethyl acetate and made alkaline by addition of 2M aq. Na₂CO₃ solution. The mixture was afterwards extracted two times with 300 ml ethyl acetate each. The combined organic phases were washed two times with 200 ml water each, dried with MgSO₄ and evaporated to dryness. The residue was used without further purification in the synthesis of intermediate 9. (m/e): 265.0 (MH⁺; 100%).

Intermediate 8

6-(4-Isobutyl-piperazin-1-yl)-pyridin-3-ylamine

A mixture of 2.48 g 1-isobutyl-4-(5-nitro-pyridin-2-yl)-piperazine (intermediate 7) and 0.8 g Pd/C (10%) in 30 ml methanol was treated with 1 bar hydrogen at room temperature for 2 h. After filtration the mixture was evaporated to dryness to yield 2.09 g (95%) of the title compound as colourless solid. (m/e): 235.0 (MH⁺; 100%).

Example 1

1-[6-(4-Ethyl-piperazin-1-yl)-pyridin-3-yl]-3-propyl-urea

A mixture of 20 mg (0.1 mmol) 6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine, 15 mg (0.15 mmol) triethylamine and 9.4 mg (0.11 mmol) 1-isocyanato-propane in 1 ml DCM was stirred at room temperature for 16 h. After evaporation the residue was taken up in 1 ml methanol/acetonitrile 1/1 and subjected to preparative HPLC purification on reversed phase eluting with a gradient of acetonitrile / water (0.05 % triethylamine). The combined product fractions were evaporated to dryness to yield 15.5 mg (53%) of the title compound. (m/e): 292.3 (MH⁺; 100%).

According to the procedure described for the synthesis of Example 1 further pyridine derivatives have been synthesized from the intermediates 2, 4, 6 and 8, respectively, and commercially available reagents listed in table 1. The examples are compiled in table 1 and comprise Examples No 2 to 60.
<table>
<thead>
<tr>
<th>No</th>
<th>MW</th>
<th>Name</th>
<th>Starting materials</th>
<th>MH+ found</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>331.46</td>
<td>1-cyclohexyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and 1-isocyanato-cyclohexane</td>
<td>332</td>
</tr>
<tr>
<td>3</td>
<td>339.44</td>
<td>1-benzyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and 1-isocyanatomethyl-benzene</td>
<td>340.3</td>
</tr>
<tr>
<td>4</td>
<td>339.44</td>
<td>1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-p-tolyl-urea</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and 1-isocyanato-4-methyl-benzene</td>
<td>340.3</td>
</tr>
<tr>
<td>5</td>
<td>365.48</td>
<td>1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and ((1R,2S)-2-isocyanato-cyclopropyl)-benzene</td>
<td>366.3</td>
</tr>
<tr>
<td>6</td>
<td>355.44</td>
<td>1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and 1-isocyanato-3-methoxy-benzene</td>
<td>355.8</td>
</tr>
<tr>
<td>7</td>
<td>343.41</td>
<td>1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-fluoro-phenyl)-urea</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and 1-isocyanato-4-fluoro-benzene</td>
<td>344.2</td>
</tr>
<tr>
<td>8</td>
<td>371.53</td>
<td>1-cyclohexyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and 1-isocyanato-cyclohexane</td>
<td>372.3</td>
</tr>
<tr>
<td>9</td>
<td>379.51</td>
<td>1-benzyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and 1-isocyanato-methylbenzene</td>
<td>380.4</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>10</td>
<td>393.53</td>
<td>1-{6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl}-3-(4-methyl-benzyl)-urea</td>
<td>6-{(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and 1-isocyanatomethyl-4-methylbenzene</td>
<td>394.2</td>
</tr>
<tr>
<td>11</td>
<td>405.55</td>
<td>1-{6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl}-3-((1R,2S)-2-phenyl-cyclopropyl)-urea</td>
<td>6-{(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and ((1R,2S)-2-isocyanato-cyclopropyl)-benzene</td>
<td>406.5</td>
</tr>
<tr>
<td>12</td>
<td>383.47</td>
<td>1-{6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl}-3-(4-fluoro-phenyl)-urea</td>
<td>6-{(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and 1-isocyanato-4-fluorobenzene</td>
<td>383.9</td>
</tr>
<tr>
<td>13</td>
<td>345.49</td>
<td>1-cyclohexyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-{(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and isocyanato-cyclohexane</td>
<td>345.3</td>
</tr>
<tr>
<td>14</td>
<td>339.44</td>
<td>1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-phenyl-urea</td>
<td>6-{(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and isocyanato-benzene</td>
<td>340.2</td>
</tr>
<tr>
<td>15</td>
<td>353.47</td>
<td>1-benzyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-{(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and isocyanatomethyl-benzene</td>
<td>354.3</td>
</tr>
<tr>
<td>16</td>
<td>353.47</td>
<td>1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-o-tolyl-urea</td>
<td>6-{(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and 1-isocyanato-2-methyl-benzene</td>
<td>353.9</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>17</td>
<td>353.47</td>
<td>1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-m-tolyl-urea</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and 1-isocyanato-3-methyl-benzene</td>
<td>354.3</td>
</tr>
<tr>
<td>18</td>
<td>373.89</td>
<td>1-(2-chloro-phenyl)-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and 1-isocyanato-2-chloro-benzene</td>
<td>374.2</td>
</tr>
<tr>
<td>19</td>
<td>367.5</td>
<td>1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and isocyanatomethyl-4-methyl-benzene</td>
<td>368.2</td>
</tr>
<tr>
<td>20</td>
<td>379.51</td>
<td>1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and ((1R,2S)-2-isocyanato-cyclopropyl)-benzene</td>
<td>379.9</td>
</tr>
<tr>
<td>21</td>
<td>369.47</td>
<td>1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and 1-isocyanato-3-methoxy-benzene</td>
<td>370.3</td>
</tr>
<tr>
<td>22</td>
<td>357.43</td>
<td>1-(4-fluoro-phenyl)-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and 1-isocyanato-4-fluoro-benzene</td>
<td>358.2</td>
</tr>
<tr>
<td>23</td>
<td>319.45</td>
<td>1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-propyl-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and 1-isocyanato-propane</td>
<td>327.3</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>-------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>24</td>
<td>359.52</td>
<td>1-cyclohexyl-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and isocyanato-cyclohexane</td>
<td>359.9</td>
</tr>
<tr>
<td>25</td>
<td>367.5</td>
<td>1-benzyl-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and isocyanatomethyl-benzene</td>
<td>368.2</td>
</tr>
<tr>
<td>26</td>
<td>367.5</td>
<td>1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-m-tolyl-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and 1-isocyanato-3-methyl-benzene</td>
<td>368.2</td>
</tr>
<tr>
<td>27</td>
<td>367.5</td>
<td>1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-p-tolyl-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and 1-isocyanato-4-methyl-benzene</td>
<td>368.2</td>
</tr>
<tr>
<td>28</td>
<td>387.91</td>
<td>1-(2-chloro-phenyl)-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and 1-isocyanato-2-chloro-benzene</td>
<td>387.9</td>
</tr>
<tr>
<td>29</td>
<td>381.52</td>
<td>1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and isocyanatomethyl-4-methyl-benzene</td>
<td>382</td>
</tr>
<tr>
<td>30</td>
<td>393.53</td>
<td>1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and ((1R,2S)-2-isocyanato-cyclopropyl)-benzene</td>
<td>393.9</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>31</td>
<td>383.5</td>
<td>1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and 1-isocyanato-3-methoxy-benzene</td>
<td>384.3</td>
</tr>
<tr>
<td>32</td>
<td>371.46</td>
<td>1-[4-fluoro-phenyl]-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea</td>
<td>6-(4-isobutyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 8) and 1-isocyanato-4-fluoro-benzene</td>
<td>371.4</td>
</tr>
<tr>
<td>33</td>
<td>313.42</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and dimethylaminosulfamoylchloride</td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>353.49</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and dimethylaminosulfamoylchloride</td>
<td></td>
</tr>
<tr>
<td>35</td>
<td>327.45</td>
<td>N-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and dimethylaminosulfamoylchloride</td>
<td></td>
</tr>
<tr>
<td>36</td>
<td>316.45</td>
<td>cyclohexanecarboxylic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-amide</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and cyclohexanecarbonyl chloride</td>
<td>317.3</td>
</tr>
<tr>
<td>37</td>
<td>324.43</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-phenyl-acetamide</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and phenyl-acetyl chloride</td>
<td>325.4</td>
</tr>
<tr>
<td>38</td>
<td>342.42</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-(4-fluoro-phenyl)-acetamide</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and (4-fluoro-phenyl)-acetyl chloride</td>
<td>343.2</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>----</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>39</td>
<td>354.45</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-(3-methoxy-phenyl)-acetamide</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and (3-methoxy-phenyl)-acetyl chloride</td>
<td>355.4</td>
</tr>
<tr>
<td>40</td>
<td>384.48</td>
<td>2-(3,4-dimethoxy-phenyl)-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-acetamide</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and (3,4-dimethoxy-phenyl)-acetyl chloride</td>
<td>385.3</td>
</tr>
<tr>
<td>41</td>
<td>308.38</td>
<td>[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid 2-methoxy-ethyl ester</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and 2-methoxy-ethanol carbonyl chloride</td>
<td>309.4</td>
</tr>
<tr>
<td>42</td>
<td>306.41</td>
<td>[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester</td>
<td>6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 2) and carbonic acid chloride monoisobutyl ester</td>
<td>307.4</td>
</tr>
<tr>
<td>43</td>
<td>314.43</td>
<td>cyclopropanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and cyclopropanecarbonyl chloride</td>
<td>315.2</td>
</tr>
<tr>
<td>44</td>
<td>316.45</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-butyramide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and butyryl chloride</td>
<td>317.3</td>
</tr>
<tr>
<td>45</td>
<td>328.46</td>
<td>cyclobutanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and cyclobutanecarbonyl chloride</td>
<td>329.4</td>
</tr>
<tr>
<td>46</td>
<td>342.49</td>
<td>cyclopentanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and cyclopentanecarbonyl chloride</td>
<td>343.4</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>47</td>
<td>344.5</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-ethyl-butyramide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and 2-ethyl-butyryl chloride</td>
<td>345.3</td>
</tr>
<tr>
<td>48</td>
<td>356.51</td>
<td>cyclohexanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and cyclohexanecarbonyl chloride</td>
<td>357.3</td>
</tr>
<tr>
<td>49</td>
<td>385.9</td>
<td>2-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-nicotinamide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and 2-chloro-nicotinoyl chloride</td>
<td>386.3</td>
</tr>
<tr>
<td>50</td>
<td>364.49</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-phenyl-acetamide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and phenyl-acetyl chloride</td>
<td>365.4</td>
</tr>
<tr>
<td>51</td>
<td>382.48</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(4-fluoro-phenyl)-acetamide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and (4-fluoro-phenyl)-acetyl chloride</td>
<td>383.3</td>
</tr>
<tr>
<td>52</td>
<td>394.52</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3-methoxy-phenyl)-acetamide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and (3-methoxy-phenyl)-acetyl chloride</td>
<td>395.3</td>
</tr>
<tr>
<td>53</td>
<td>424.54</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3,4-dimethoxy-phenyl)-acetamide</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and (3,4-dimethoxy-phenyl)-acetyl chloride</td>
<td>425.3</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>54</td>
<td>318.42</td>
<td>[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid ethyl ester</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and carbonic acid monoethyl ester</td>
<td>319.3</td>
</tr>
<tr>
<td>55</td>
<td>348.45</td>
<td>[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid 2-methoxy-ethyl ester</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and carbonic acid mono (2-methoxyethyl) ester</td>
<td>349.4</td>
</tr>
<tr>
<td>56</td>
<td>346.47</td>
<td>[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester</td>
<td>6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 6) and carbonic acid monoisobutyl ester</td>
<td>347.3</td>
</tr>
<tr>
<td>57</td>
<td>330.48</td>
<td>cyclohexanecarboxylic acid [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amide</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and cyclohexanecarbonyl chloride</td>
<td>331.3</td>
</tr>
<tr>
<td>58</td>
<td>398.51</td>
<td>2-(3,4-dimethoxy-phenyl)-N-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-acetamide</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and (3,4-dimethoxy-phenyl)-acetyl chloride</td>
<td>399.2</td>
</tr>
<tr>
<td>59</td>
<td>292.38</td>
<td>[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid ethyl ester</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and carbonic acid monoethyl ester</td>
<td>293.3</td>
</tr>
<tr>
<td>60</td>
<td>320.44</td>
<td>[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester</td>
<td>6-(4-isopropyl-piperazin-1-yl)-pyridin-3-ylamine (intermediate 4) and carbonic acid monoisobutyl ester</td>
<td>321.3</td>
</tr>
</tbody>
</table>
Intermediate 9

6-(4-Ethyl-piperazin-1-yl)-nicotinonitrile

A mixture of 2 g (14 mmol) 6-chloronicotinonitrile (commercially available) and 0.88 g (7 mmol) N,N-diisopropylethylamine in 20 ml water and 4 ml DMF was heated to 80 °C. During 2 min 1.98 g (17 mmol) N-ethylpiperazine was added and stirred at 80 °C for 1 h. 100 ml 1M aq. Na₂CO₃ solution was added and the mixture was extracted three times with 100 ml ethyl acetate each. The combined organic phases were washed twice with 100 ml brine each and dried with MgSO₄. After evaporation the residue was purified with flash chromatography on Alox eluting with a gradient of ethyl acetate / heptan to yield 1.4 g (45 %) of the title compound as slightly yellow crystals. (m/e): 21702 (MH⁺; 100%).

Intermediate 10

C-[6-(4-Ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine

A mixture of 2 g (8 mmol) 6-(4-ethyl-piperazin-1-yl)-nicotinonitrile, 1.3 g Raney Nickel (B113Z, Degussa) in 25 ml methanol, 15 ml ethyl acetate and 5 ml ammonia aq. (ca. 25 %) was treated with 1 bar hydrogen at 30-35 °C for 4 h. The mixture was filtered and the residue washed three times with 20 ml ethyl acetate each and the combined organic phases evaporated to dryness to yield 1.83 g (97 %) of the title compound as white crystals. (m/e): 261.1 (MH⁺; 100%).

Intermediate 11

6-(4-Cyclopentyl-piperazin-1-yl)-nicotinonitrile

A mixture of 2 g (14 mmol) 6-chloronicotinonitrile (commercially available) 2.45 g (16 mmol) N-cyclopentylpiperazine (commercially available) and 1.86 g (14 mmol) N,N-diisopropylethylamine in 5 ml water and 15 ml DMF was heated to 90 °C for 24 h. After addition of 250 ml 1M NaHCO₃ aq. solution the mixture was extracted three times with 250 ml ethyl acetate each. The combined organic phases were washed twice with 150 ml brine each, dried and evaporated to dryness. Recrystallisation from ethyl acetate yielded a first batch of 2.83 g of white crystals. An additional batch was yielded from the filtrate and in total 3.14 g (85 %) of the title compound was obtained as white crystals. (m/e): 257.1 (MH⁺; 100%).
Intermediate 12

C-[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine

According to the procedure described for the synthesis of intermediate 10 C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine was synthesized from 6-(4-cyclopentyl-piperazin-1-yl)-nicotininitrile through hydrogenation over Raney Nickel.

1.99 g (98 %) of the title compounds was obtained as white crystals. (m/e): 261.1 (MH⁺; 100%).

Example 61

N-[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-butyramide

A mixture of 26 mg (0.1 mmol) C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine, 20 mg (0.2 mmol) triethylamine and 12 mg (0.11 mmol) butyryl chloride in DCM was stirred at room temperature. After evaporation acetonitrile / DMF was added and the mixture was subjected to preparative HPLC purification on reversed phase eluting with a gradient of acetonitrile / water (0.05 % triethylamine). The combined product fractions were evaporated to dryness to yield 20.3 mg (61 %) of the title compound. (m/e): 331.3

According to the procedure described for the synthesis of example 73 further pyridine derivatives have been synthesized from C-[6-(4-Ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine and C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine and the respective commercially available reagent mentioned in Table 2. The Examples are shown in table 2 and comprise Examples No 62 to 90.

Table 2

<table>
<thead>
<tr>
<th>No</th>
<th>MW</th>
<th>Name</th>
<th>Starting materials</th>
<th>MH⁺ found</th>
</tr>
</thead>
<tbody>
<tr>
<td>62</td>
<td>394.52</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 3-methoxy-benzoyl chloride</td>
<td>395.3</td>
</tr>
<tr>
<td>63</td>
<td>378.52</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and phenyl-acetyl chloride</td>
<td>379.4</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>64</td>
<td>396.51</td>
<td>N-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-(4-fluoro-phenyl)-acetamide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and (4-fluoro-phenyl)-acetyl chloride</td>
<td>397.4</td>
</tr>
<tr>
<td>65</td>
<td>352.5</td>
<td>ethanesulfonic acid [6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and ethanesulfonyl chloride</td>
<td>353.3</td>
</tr>
<tr>
<td>66</td>
<td>366.53</td>
<td>propane-1-sulfonic acid [6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and propanesulfonyl chloride</td>
<td>367.2</td>
</tr>
<tr>
<td>67</td>
<td>367.52</td>
<td>N-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and dimethylaminosulfamoylchloride</td>
<td>368.2</td>
</tr>
<tr>
<td>68</td>
<td>400.54</td>
<td>N-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and benzenesulfonyl chloride</td>
<td>401.5</td>
</tr>
<tr>
<td>69</td>
<td>414.57</td>
<td>N-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenylmethanesulfonamide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and phenyl-methanesulfonyl chloride</td>
<td>415.4</td>
</tr>
<tr>
<td>70</td>
<td>449.02</td>
<td>C-(4-chloro-phenyl)-N-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-methanesulfonamide</td>
<td>C-[6-(4-cyclo pentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 4-chloro-phenyl-methanesulfonyl chloride</td>
<td>449.3</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>71</td>
<td>418.53</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-fluorobenzenesulfonamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 2-fluoro-benzenesulfonyl chloride</td>
<td>419.3</td>
</tr>
<tr>
<td>72</td>
<td>418.53</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-fluorobenzenesulfonamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 3-fluoro-benzenesulfonyl chloride</td>
<td>419.3</td>
</tr>
<tr>
<td>73</td>
<td>418.53</td>
<td>N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-4-fluorobenzenesulfonamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 4-fluoro-benzenesulfonyl chloride</td>
<td>419.3</td>
</tr>
<tr>
<td>74</td>
<td>434.99</td>
<td>2-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]benzenesulfonamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 2-chloro-benzenesulfonyl chloride</td>
<td>435.3</td>
</tr>
<tr>
<td>75</td>
<td>434.99</td>
<td>4-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]benzenesulfonamide</td>
<td>C-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 12) and 4-chloro-benzenesulfonyl chloride</td>
<td>435.3</td>
</tr>
<tr>
<td>76</td>
<td>371.46</td>
<td>1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-(4-fluoro-benzyl)-urea</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 1-fluoro-4-isocyanatomethyl-benzene</td>
<td>372.3</td>
</tr>
<tr>
<td>77</td>
<td>354.45</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 3-methoxybenzoylchloride</td>
<td>355.3</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>-----</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>78</td>
<td>338.45</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and phenyl-acetyl chloride</td>
<td>339.2</td>
</tr>
<tr>
<td>79</td>
<td>356.44</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-(4-fluoro-phenyl)-acetamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 4-fluoro-phenyl acetyl chloride</td>
<td>357.3</td>
</tr>
<tr>
<td>80</td>
<td>312.44</td>
<td>ethanesulfonic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and ethanesulfonylchloride</td>
<td>313</td>
</tr>
<tr>
<td>81</td>
<td>326.46</td>
<td>propane-1-sulfonic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and propanesulfonylchloride</td>
<td>327.3</td>
</tr>
<tr>
<td>82</td>
<td>327.45</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminosulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and dimethylaminosulfamoylchloride</td>
<td>328.2</td>
</tr>
<tr>
<td>83</td>
<td>360.48</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and benzenesulfonyl chloride</td>
<td>361.3</td>
</tr>
<tr>
<td>84</td>
<td>374.51</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenyl-methanesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and phenyl-methanesulfonyl chloride</td>
<td>375.4</td>
</tr>
<tr>
<td>No</td>
<td>MW</td>
<td>Name</td>
<td>Starting materials</td>
<td>MH+ found</td>
</tr>
<tr>
<td>----</td>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>85</td>
<td>408.95</td>
<td>C-(4-Chloro-phenyl)-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-methanesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 4-chloro-phenyl-methanesulfonyl chloride</td>
<td>409.3</td>
</tr>
<tr>
<td>86</td>
<td>378.47</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-fluorobenzenesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 2-fluoro-benzenesulfonyl chloride</td>
<td>379.3</td>
</tr>
<tr>
<td>87</td>
<td>378.47</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-fluorobenzenesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 3-fluoro-benzenesulfonyl chloride</td>
<td>379.3</td>
</tr>
<tr>
<td>88</td>
<td>378.47</td>
<td>N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-4-fluorobenzenesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 4-fluoro-benzenesulfonyl chloride</td>
<td>379.3</td>
</tr>
<tr>
<td>89</td>
<td>394.92</td>
<td>2-chloro-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 2-chloro-benzenesulfonyl chloride</td>
<td>395.3</td>
</tr>
<tr>
<td>90</td>
<td>394.92</td>
<td>4-chloro-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide</td>
<td>C-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-methylamine (intermediate 10) and 4-chloro-benzenesulfonyl chloride</td>
<td>395.3</td>
</tr>
</tbody>
</table>
Example 91

4-Methyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

A mixture of 29 mg (0.08 mmol) [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid phenyl ester (intermediately built from intermediate 6 and phenylchloroformate) and 12 mg (0.12 mmol) 4-methyl-piperidine (commercially available) in 1ml DCM and 0.1 ml DMF was stirred at room temperature for 16 h. After evaporation the residue was taken up in methanol/DMF and subjected to preparative HPLC purification on reversed phase eluting with a gradient of acetonitrile / water (0.05 % triethylamine). The combined product fractions were evaporated to dryness to yield 13.6 mg (46 %) of the title compound. (m/e): 372.3 (MH⁺; 100%).

Example 92

2,6-Dimethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 2,6-dimethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and 2,6-dimethyl-piperidine (commercially available). (m/e): 372.3 (MH⁺; 100%).

Example 93

4-Trifluoromethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 4-trifluoromethyl-piperidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and 4-trifluoromethyl-piperidine (commercially available). (m/e): 426.3 (MH⁺; 100%).

Example 94

1-[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-ylcarbamoyl]-piperidine-4-carboxylic acid ethyl ester

According to the procedure described for the synthesis of Example 91 1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylcarbamoyle]-piperidine-4-carboxylic
acid ethyl ester was synthesised from intermediate 6 and piperidine-4-carboxylic acid ethyl ester (commercially available). (m/e): 430.4 (MH⁺; 100%).

Example 95

Octahydro-quinoline-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 octahydro-quinoline-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and 2,6-dimethyl-piperidine (commercially available). (m/e): 412.5 (MH⁺; 100%).

Example 96

Octahydro-isoquinoline-2-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 octahydro-isoquinoline-2-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and octahydro-isoquinoline (commercially available). (m/e): 412.5 (MH⁺; 100%).

Example 97

2-trifluoromethyl-pyrrolidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 2-trifluoromethyl-pyrrolidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and 2-trifluoromethyl-pyrrolidine (commercially available). (m/e): 412.4 (MH⁺; 100%).

Example 98

2-Isopropyl-pyrrolidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 2-isopropyl-pyrrolidine-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and 2-isopropyl-pyrrolidine (commercially available). (m/e): 386.3 (MH⁺; 100%).
Example 99

1,3-Dihydro-isoindole-2-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91, 1,3-dihydro-isoindole-2-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and 1,3-dihydro-isoindole (commercially available). (m/e): 392.2 (MH⁺; 100%).

Example 100

3-[[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-isopropyl-1-(2-methoxy-ethyl)-urea

According to the procedure described for the synthesis of Example 91, 3-[[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-isopropyl-1-(2-methoxy-ethyl)-urea was synthesised from intermediate 6 and isopropyl-2-methoxyethyl-amine (commercially available). (m/e): 390.4 (MH⁺; 100%).

Example 101

Azepane-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91, azepane-1-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 6 and azepine (commercially available). (m/e): 372.3 (MH⁺; 100%).

Example 102

3-[[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-ethyl-1-phenyl-urea

According to the procedure described for the synthesis of Example 91, 3-[[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-ethyl-1-phenyl-urea was synthesised from intermediate 6 and ethylphenylamine (commercially available). (m/e): 394.4 (MH⁺; 100%).

Example 103

3-[[6-(4-Cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-(4-methoxy-phenyl)-1-methyl-urea

According to the procedure described for the synthesis of Example 91, 3-[[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-1-(4-methoxy-phenyl)-1-methyl-urea was
synthesised from intermediate 6 and (4-methoxy-phenyl)-methyl-amine (commercially available). (m/e): 410.4 (MH⁺; 100%).

**Example 104**

3,4-Dihydro-2H-quinoline-1-carboxylic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 3,4-dihydro-2H-quinoline-1-carboxylic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 2 and 3,4-dihydro-2H-quinoline (commercially available). (m/e): 366.3 (MH⁺; 100%).

**Example 105**

3,4-Dihydro-2H-quinoline-1-carboxylic acid [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amide

According to the procedure described for the synthesis of Example 91 3,4-dihydro-2H-quinoline-1-carboxylic acid [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amide was synthesised from intermediate 4 and 3,4-dihydro-2H-quinoline (commercially available). (m/e): 380.3 (MH⁺; 100%).

***
Example A

Film coated tablets containing the following ingredients can be manufactured in a conventional manner:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Per tablet</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Kernel:</strong></td>
<td></td>
</tr>
<tr>
<td>Compound of formula (I)</td>
<td>10.0 mg</td>
</tr>
<tr>
<td>Microcrystalline cellulose</td>
<td>23.5 mg</td>
</tr>
<tr>
<td>Lactose hydrous</td>
<td>60.0 mg</td>
</tr>
<tr>
<td>Povidone K30</td>
<td>12.5 mg</td>
</tr>
<tr>
<td>Sodium starch glycolate</td>
<td>12.5 mg</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>1.5 mg</td>
</tr>
<tr>
<td><em>(Kernel Weight)</em></td>
<td>120.0 mg</td>
</tr>
</tbody>
</table>

**Film Coat:**

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hydroxypropyl methyl cellulose</td>
<td>3.5 mg</td>
</tr>
<tr>
<td>Polyethylene glycol 6000</td>
<td>0.8 mg</td>
</tr>
<tr>
<td>Talc</td>
<td>1.3 mg</td>
</tr>
<tr>
<td>Iron oxyde (yellow)</td>
<td>0.8 mg</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>0.8 mg</td>
</tr>
</tbody>
</table>

The active ingredient is sieved and mixed with microcrystalline cellulose and the mixture is granulated with a solution of polyvinylpyrrolidone in water. The granulate is mixed with sodium starch glycolate and magnesium stearate and compressed to yield kernels of 120 or 350 mg respectively. The kernels are lacquered with an aqueous solution/suspension of the above mentioned film coat.
Example B

Capsules containing the following ingredients can be manufactured in a conventional manner:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Per capsule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of formula (I)</td>
<td>25.0 mg</td>
</tr>
<tr>
<td>Lactose</td>
<td>150.0 mg</td>
</tr>
<tr>
<td>Maize starch</td>
<td>20.0 mg</td>
</tr>
<tr>
<td>Talc</td>
<td>5.0 mg</td>
</tr>
</tbody>
</table>

The components are sieved and mixed and filled into capsules of size 2.

Example C

Injection solutions can have the following composition:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of formula (I)</td>
<td>3.0 mg</td>
</tr>
<tr>
<td>Gelatine</td>
<td>150.0 mg</td>
</tr>
<tr>
<td>Phenol</td>
<td>4.7 mg</td>
</tr>
<tr>
<td>Sodium carbonate</td>
<td>to obtain a final pH of 7</td>
</tr>
<tr>
<td>Water for injection solutions</td>
<td>ad 1.0 ml</td>
</tr>
</tbody>
</table>
Example D

Soft gelatin capsules containing the following ingredients can be manufactured in a conventional manner:

**Capsule contents**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Weight (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Compound of formula (I)</td>
<td>5.0</td>
</tr>
<tr>
<td>Yellow wax</td>
<td>8.0</td>
</tr>
<tr>
<td>Hydrogenated Soya bean oil</td>
<td>8.0</td>
</tr>
<tr>
<td>Partially hydrogenated plant oils</td>
<td>34.0</td>
</tr>
<tr>
<td>Soya bean oil</td>
<td>110.0</td>
</tr>
<tr>
<td>Weight of capsule contents</td>
<td>165.0</td>
</tr>
</tbody>
</table>

**Gelatin capsule**

<table>
<thead>
<tr>
<th>Ingredient</th>
<th>Weight (mg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gelatin</td>
<td>75.0</td>
</tr>
<tr>
<td>Glycerol 85 %</td>
<td>32.0</td>
</tr>
<tr>
<td>Karion 83</td>
<td>8.0 (dry matter)</td>
</tr>
<tr>
<td>Titanium dioxide</td>
<td>0.4</td>
</tr>
<tr>
<td>Iron oxide yellow</td>
<td>1.1</td>
</tr>
</tbody>
</table>

The active ingredient is dissolved in a warm melting of the other ingredients and the mixture is filled into soft gelatin capsules of appropriate size. The filled soft gelatin capsules are treated according to the usual procedures.
Example E

Sachets containing the following ingredients can be manufactured in a conventional manner:

- Compound of formula (I) 50.0 mg
- Lactose, fine powder 1015.0 mg
- Microcristalline cellulose (AVICEL PH 102) 1400.0 mg
- Sodium carboxymethyl cellulose 14.0 mg
- Polyvinylpyrrolidone K 30 10.0 mg
- Magnesium stearate 10.0 mg
- Flavoring additives 1.0 mg

The active ingredient is mixed with lactose, microcristalline cellulose and sodium carboxymethyl cellulose and granulated with a mixture of polyvinylpyrrolidone in water. The granulate is mixed with magnesium stearate and the flavouring additives and filled into sachets.
Claims

1. Compounds of the general formula

\[
R^2-X-N-(CH_2)_m-N=N=O-N-R^1
\]

wherein

5 \( R^1 \) is selected from the group consisting of hydrogen, lower alkyl, C\(_3\)-C\(_7\)-alkenyl, C\(_3\)-C\(_7\)-alkynyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, C\(_3\)-C\(_7\)-cycloalkyl, and lower C\(_3\)-C\(_7\)-cycloalkylalkyl;

X is C(O) or SO\(_2\);

m is 0 or 1;

10 \( R^2 \) is selected from the group consisting of lower alkyl, C\(_3\)-C\(_7\)-alkenyl, C\(_3\)-C\(_7\)-alkynyl, lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl, unsubstituted C\(_3\)-C\(_7\)-cycloalkyl or C\(_3\)-C\(_7\)-cycloalkyl substituted by phenyl, lower C\(_3\)-C\(_7\)-cycloalkylalkyl, lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, unsubstituted pyridyl or pyridyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and -NR\(^3\)R\(^4\),

or, in case X is C(O), R\(^2\) can also be lower alkoxy or lower alkoxyalkoxy,

or, in case m is 1, R\(^2\) can also be unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl,

\( R^3 \) is hydrogen or lower alkyl;

\( R^4 \) is selected from the group consisting of lower alkyl, C\(_3\)-C\(_7\)-alkenyl, C\(_3\)-C\(_7\)-alkynyl, lower alkoxyalkyl,

C\(_3\)-C\(_7\)-cycloalkyl,

C\(_3\)-C\(_7\)-cycloalkyl substituted by phenyl,

lower C\(_3\)-C\(_7\)-cycloalkylalkyl,

unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower
alkoxy, halogen or lower halogenalkyl, and
lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by
lower alkyl, lower alkoxy, halogen or lower halogenalkyl; or

$R^3$ and $R^4$ together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or
7-membered heterocyclic ring optionally containing a further heteroatom selected
from nitrogen, oxygen or sulfur, said heterocyclic ring being unsubstituted or
substituted by one, two or three groups independently selected from lower alkyl,
lower alkoxy, lower alkoxy carbonyl, oxo, halogen and halogenalkyl, or being
condensed with a $C_5$-$C_6$-cycloalkyl ring or a phenyl ring, said cycloalkyl ring or
phenyl ring being unsubstituted or substituted by one, two or three groups
independently selected from lower alkyl, lower alkoxy, halogen and halogenalkyl;
and pharmaceutically acceptable salts thereof;

with the exception of 2,2-dimethyl-N-[6-(4-methyl-piperazin-1-yl)-pyridin-3-yl]-
propionamide.

2. Compounds of formula I according to claim 1, wherein $R^1$ is lower alkyl or
$C_3$-$C_7$-cycloalkyl.

3. Compounds of formula I according to claims 1 or 2, wherein $R^1$ is $C_3$-$C_7$-
cycloalkyl.

4. Compounds of formula I according to any of claims 1 to 3, wherein $R^1$ is ethyl or
isopropyl.

5. Compounds of formula I according to any of claims 1 to 4, wherein $m$ is 1.

6. Compounds of formula I according to any of claims 1 to 4, wherein $m$ is 0.

7. Compounds of formula I according to any of claims 1 to 6, wherein $R^2$ is selected
from the group consisting of
lower alkyl, $C_3$-$C_7$-alkenyl, $C_3$-$C_7$-alkinyl,
lower halogenalkyl, lower hydroxyalkyl, lower alkoxyalkyl,
unsubstituted $C_3$-$C_7$-cycloalkyl or $C_3$-$C_7$-cycloalkyl substituted by phenyl,
lower $C_3$-$C_7$-cycloalkylalkyl,
lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower
alkyl, lower alkoxy, halogen or lower halogenalkyl,
unsubstituted pyridyl or pyridyl mono- or disubstituted by lower alkyl, lower alkoxy,
halogen or lower halogenalkyl, and
-NR²R⁴,
or, in case X is C(O), R² can also be lower alkoxy or lower alkoxyalkoxy.

8. Compounds of formula I according to any of claims 1 to 7, wherein R² is selected
from the group consisting of lower alkyl, C₃-C₇-cycloalkyl and C₃-C₇-cycloalkyl
substituted by phenyl.

9. Compounds of formula I according to any of claims 1 to 7, wherein R² is lower
phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl,
lower alkoxy, halogen or lower halogenalkyl.

10. Compounds of formula I according to any of claims 1 to 7, wherein R² is
-NR³R⁴ and R³ and R⁴ are as defined in claim 1.

11. Compounds of formula I according to any of claims 1 to 7 or 10, wherein
R³ is hydrogen or lower alkyl;
R⁴ is selected from the group consisting of lower alkyl, C₃-C₇-alkenyl, C₃-C₇-alkeny1,
C₃-C₇-cycloalkyl,
C₃-C₇-cycloalkyl substituted by phenyl,
lower C₃-C₇-cycloalkylalkyl,
unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower
alkoxy, halogen or lower halogenalkyl, and
lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by
lower alkyl, lower alkoxy, halogen or lower halogenalkyl; or
R³ and R⁴ together with the nitrogen atom to which they are attached form a 4-, 5-, 6- or
7-membered heterocyclic ring optionally containing a further heteroatom selected
from nitrogen, oxygen or sulfur, said heterocyclic ring being unsubstituted or
substituted by one, two or three groups independently selected from lower alkyl,
lower alkoxy, oxo, halogen and halogenalkyl, or being condensed with a phenyl
ring, said phenyl ring being unsubstituted or substituted by one, two or three
groups independently selected from lower alkyl, lower alkoxy, halogen and
halogenalkyl.
12. Compounds of formula I according to claims 10 or 11, wherein R³ and R⁴ are lower alkyl.

13. Compounds of formula I according to claims 10 or 11, wherein R³ is hydrogen and R⁴ is selected from the group consisting of lower alkyl, C₅-C₇-alkenyl, C₃-C₇-alkynyl, C₃-C₇-cycloalkyl, C₃-C₇-cycloalkyl substituted by phenyl, lower C₃-C₇-cycloalkylalkyl, unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl, and lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl.

14. Compounds of formula I according to claims 10 or 11, wherein R³ is hydrogen and R⁴ is lower phenylalkyl wherein phenyl is unsubstituted or mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl.

15. Compounds of formula I according to any of claims 1 to 5, wherein m is 1 and R² is unsubstituted phenyl or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or lower halogenalkyl.

16. Compounds of formula I according to any of claims 1 to 15, wherein X is SO₂.

17. Compounds of formula I according to any of claims 1 to 15, wherein X is C(O).

18. Compounds of formula I according to any of claims 1 to 15, wherein X is C(O) and R² is –NR³R⁴.

19. Compounds of formula I according to claim 1, selected from the group consisting of
1-[6-(4-ethylpiperazin-1-yl)-pyridin-3-yl]-3-propyl-urea,
1-cyclohexyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-p-tolyl-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea,
1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-fluoro-phenyl)-urea,
1-cyclohexyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,
1-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,
1-cyclohexyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-phenyl-urea,
1-benzyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-o-tolyl-urea,
1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-m-tolyl-urea,
1-(2-chloro-phenyl)-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,
1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,
1-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea,
1-(4-fluoro-phenyl)-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-propyl-urea,
cyclohexyl-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-m-tolyl-urea,
1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-p-tolyl-urea,
1-(2-chloro-phenyl)-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,
1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-((1R,2S)-2-phenyl-cyclopropyl)-urea,
1-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-3-(3-methoxy-phenyl)-urea,
1-(4-fluoro-phenyl)-3-[6-(4-isobutyl-piperazin-1-yl)-pyridin-3-yl]-urea,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
N-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
cyclohexanecarboxylic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-amide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-phenyl-acetamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-(4-fluoro-phenyl)-acetamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-2-(3-methoxy-phenyl)-acetamide,
2-(3,4-dimethoxy-phenyl)-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-acetamide,
[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid 2-methoxy-ethyl ester,
[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyl ester,
cyclopropane-carboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-butyramide,
cyclobutanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide, cyclopentanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-ethyl-butyramide, cyclohexanecarboxylic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-amide, 2-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-nicotinamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-phenyl-acetamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(4-fluoro-phenyl)-acetamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3-methoxy-phenyl)-acetamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3,4-dimethoxy-phenyl)-acetamide, [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid ethyl ester, [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid 2-methoxy-ethyl ester, [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyyl ester, cyclohexanecarboxylic acid [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-amide, 2-(3,4-dimethoxy-phenyl)-N-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-acetamide, [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid ethyl ester, [6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-carbamic acid isobutyyl ester, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-butyramide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-(4-fluoro-phenyl)-acetamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide, ethanesulfonic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide, propane-1-sulfonic acid [6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminoisulfonamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenylmethanesulfonamide, C-(4-chloro-phenyl)-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]- methanesulfonamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-fluoro-benzenesulfonamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-fluoro-benzenesulfonamide, N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-4-fluoro-benzenesulfonamide, 2-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide, 4-chloro-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide, 1-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-(4-fluoro-benzyl)-urea, N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzamide, N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide, N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-(4-fluoro-phenyl)-acetamide,
ethanesulfonic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide,
propane-1-sulfonic acid [6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-amide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminosulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenyl-methanesulfonamide,
C-(4-chloro-phenyl)-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-methanesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-fluoro-benzenesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-fluoro-benzenesulfonamide,
N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-4-fluoro-benzenesulfonamide,
2-chloro-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
4-chloro-N-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-ylmethyl]-benzenesulfonamide,
and pharmaceutically acceptable salts thereof.

20. Compounds of formula I according to claim 1, selected from the group

consisting of
1-benzyl-3-[6-(4-ethyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-benzyl-3-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-urea,
1-[6-(4-byclopentyl-piperazin-1-yl)-pyridin-3-yl]-3-(4-methyl-benzyl)-urea,
1-benzyl-3-[6-(4-isopropyl-piperazin-1-yl)-pyridin-3-yl]-urea,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-dimethylaminosulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-yl]-2-(3,4-dimethoxy-phenyl)-acacetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-3-methoxy-benzoamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-2-phenyl-acetamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-dimethylaminosulfonamide,
N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-C-phenyl-methanesulfonamide,
C-(4-chloro-phenyl)-N-[6-(4-cyclopentyl-piperazin-1-yl)-pyridin-3-ylmethyl]-methanesulfonamide,
and pharmaceutically acceptable salts thereof.
21. A process for the manufacture of compounds according to any one of claims 1 to 20, which process comprises

a) reacting a compound of the formula II

\[
\text{II}
\]

wherein \( R^1 \) and \( m \) are as defined in claim 1,

with a sulfonyl chloride or sulfamoyl chloride of the formula III

\[
\text{III}
\]

wherein \( R^2 \) is as defined in claim 1,

to obtain a compound of the formula I-A

\[
\text{I-A}
\]

wherein \( R^1, R^2 \) and \( m \) are as defined in claim 1, or

b) reacting a compound of the formula II

\[
\text{II}
\]

wherein \( R^1 \) and \( m \) are as defined in claim 1,

with a chloride of the formula IV

\[
\text{IV}
\]

wherein \( R^2 \) is as defined in claim 1,

to obtain a compound of the formula I-B
wherein $R^1$, $R^2$ and $m$ are as defined in claim 1, or

c) reacting a compound of the formula II

$$\begin{align*}
H_2N-(CH_2)_m & \quad \text{N} \quad \text{N} \quad \text{N} \quad \text{N} \quad \text{N} \quad R^1 \\
\end{align*}$$

wherein $R^1$ and $m$ are as defined in claim 1, with an isocyanate of the formula V

$$\begin{align*}
R^4 \text{-N=C=O} \\
\end{align*}$$

wherein $R^4$ is as defined in claim 1, to obtain a compound of the formula I-C

$$\begin{align*}
R^4 \text{-N=C} & \quad \text{N} \quad (CH_2)_m \quad \text{N} \quad (CH_2)_m \quad \text{N} \quad \text{N} \quad \text{N} \quad \text{N} \quad R^1 \\
\end{align*}$$

wherein $R^3$ is hydrogen and $R^1$, $R^4$ and $m$ are as defined in claim 1,

and if desired, converting the compound of formula I-A, I-B or I-C into a pharmaceutically acceptable salt.

22. Compounds according to any one of claims 1 to 20 when manufactured by a process according to claim 21.
23. Pharmaceutical compositions comprising a compound according to any one of claims 1 to 20 and a pharmaceutically acceptable carrier and/or adjuvant.

24. Pharmaceutical compositions according to claim 23 for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

25. Compounds according to any one of claims 1 to 20 for use as therapeutically active substances.

26. Compounds according to any one of claims 1 to 20 for use as therapeutically active substances for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

27. A method for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors, which method comprises administering a compound according to any one of claims 1 to 20 to a human being or animal.

28. The use of compounds according to any one of claims 1 to 20 for the preparation of medicaments for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

29. The use according to 28 for the treatment and/or prevention of obesity.

30. The novel compounds, processes and methods as well as the use of such compounds substantially as described herein before.

***
INTERNATIONAL SEARCH REPORT

International application No

A. CLASSIFICATION OF SUBJECT MATTER

INV. C07D213/82 C07D213/83 A61K31/496 A61P1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BEILSTEIN Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category*</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>WO 2006/004200 A (SANKYO COMPANY, LIMITED; KURATA, HITOSHI; UTO, YOSHIKAZU; FUJIBAYASHI,1) 12 January 2006 (2006-01-12) intermediates e.g. for the preparation of 1-8 to 1-14, 1-584, 1-586, 1-847.</td>
<td>1-30</td>
</tr>
<tr>
<td>X</td>
<td>EP 1 156 045 A (NIPPON SHINYAKU CO., LTD) 21 November 2001 (2001-11-21) 2 intermediates : piperazine derivatives cited in reference example 24</td>
<td>1,6-8, 10-13,16</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document but published on or after the international filing date
  *L* document which may throw doubts on priority claims
  *P* document published prior to the international filing date but later than the priority date claimed
  *O* document relating to an oral disclosure, use, exhibition or other means
  *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  *X* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  *X* document member of the same patent family

Date of the actual completion of the International search

21 March 2006

Date of mailing of the international search report

28/03/2006

Name and mailing address of the ISA/
European Patent Office, P.B. 5518 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 940-2040, Tx. 31 051 epos nl
Fax: (+31-70) 340-3016

Authorized officer
Gregoire, A
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
Box II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. X Claims Ncs.: because they relate to subject matter not required to be searched by this Authority, namely:

   Although claim 27 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

2. □ Claims Ncs.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. □ Claims Ncs.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. □ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. □ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. □ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Ncs.:

4. □ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Ncs.:

Remark on Protest

□ The additional search fees were accompanied by the applicant’s protest.

□ No protest accompanied the payment of additional search fees.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>WO 2006004200 A</td>
<td>12-01-2006</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0044743 A1</td>
<td>03-08-2000</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 0196327 A1</td>
<td>20-12-2001</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2004503549 T</td>
<td>05-02-2004</td>
</tr>
<tr>
<td>JP 2005239578 A</td>
<td>08-09-2005</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>